Microneedle-mediated tumor microenvironment modulation for enhanced CAR-T therapy
Revolutionary microneedle technology targets tumors to modulate the tumor microenvironment, enhancing the efficacy of CAR-T and T cell engagers. This approach promotes immunogenic cell death, increases therapeutic T cell infiltration, and overcomes tumor heterogeneity.
Overview
This innovative technology leverages dissolving microneedles (dMN) for the localized delivery of a hydrophobic natural immune modulator directly to tumor sites and tumor-draining lymph nodes (TDLN). The microneedles transform the immunosuppressive tumor microenvironment (TME) into an immunostimulatory one, enhancing the efficacy of T cell-based therapies such as T cell engagers (TCE) and CAR-T cells. By inducing immunogenic cell death and activating antigen-presenting cells, this method promotes increased infiltration and functionality of therapeutic T cells within tumors. The result is significant inhibition of tumor growth and metastasis across various solid tumors, improving the outcomes of CAR-T and TCE therapies.
Technical specifications
- Utilizes dissolving microneedles for targeted, localized administration of immune modulators
- Induces immunogenic cell death to release tumor antigens and activate antigen-presenting cells
- Promotes a polyclonal T cell response, overcoming tumor heterogeneity and preventing antigen escape
- Enhances T cell infiltration and activity within tumors
- Minimally invasive with potential for repeated administrations, improving patient compliance
Technology readiness level
The technology is currently at TRL 4, with ongoing validation through in vitro and in vivo studies. HER2+ breast cancer models are used to assess TME modulation, CAR-T cell infiltration, and immune pathway activation. Future validation includes transcriptomic analysis to confirm changes in immune-related genes and pathways.
About Sungkyunkwan University
Sungkyunkwan University (SKKU) is a comprehensive private research university with campuses in Seoul and Suwon, pairing deep heritage with a modern, industry‑oriented culture. Proximity to Samsung’s R&D and manufacturing hub and extensive on‑campus labs enable direct pathways for sponsored research, contract testing, and joint development. The medical school’s integration with a major tertiary hospital in Seoul provides access to clinical trials and device validation, while an industry–university cooperation foundation streamlines agreements and IP. Research is supported by competitive national funding from the National Research Foundation of Korea and relevant ministries, and a dedicated technology transfer office advances licensing and startup formation.
delivered to your inbox.